Benzinga | Jun 2, 2021 07:14AM EDT

Raymond James Maintains Outperform on Abbott Laboratories, Lowers Price Target to $116

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $116.